Table 7.

Survival analysis of MM patients including different treatment and auto-HSCT.

Genotypes	Patients with auto-HSCT treated with				Patients without auto-HSCT treated with
	T	B	M	p-value	T	B	M	p-value
OS (MONTHS)
II+ID	22	11.6	9.6	0.09	50.6	35	23	0.08
DD	23.5	21	6	0.31	86.2	19	18.3	0.07
ID+DD	21.2	18.4	8.1	0.18	*	*	*	*
II	32.7	14	9	0.27	53.9	27	21	0.03
PFS (MONTHS)
II+ID	29.3	35	23	0.73	13.1	10.4	9.6	0.60
DD	49.5	17	18.3	0.48	19.5	13.6	5.6	0.27
ID+DD	*	*	*	*	17	12.8	8	0.24
II	30	26	21	0.53	17.5	11.2	9	0.61

T, Thalidomide; B, bortezomib; M, Thalidomide and Bortezomib.

^*Too small group for analysis. Bold values indicate statistical significant.